HL Financial Services LLC cut its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 30.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,600 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the period. HL Financial Services LLC’s holdings in Horizon Pharma PLC were worth $147,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of the business. Alps Advisors Inc. raised its stake in Horizon Pharma PLC by 9.5% in the third quarter. Alps Advisors Inc. now owns 160,878 shares of the biopharmaceutical company’s stock valued at $2,040,000 after buying an additional 14,011 shares in the last quarter. Principal Financial Group Inc. raised its stake in Horizon Pharma PLC by 1,865.4% in the third quarter. Principal Financial Group Inc. now owns 399,132 shares of the biopharmaceutical company’s stock valued at $5,060,000 after buying an additional 378,824 shares in the last quarter. Prudential Financial Inc. raised its stake in Horizon Pharma PLC by 342.0% in the third quarter. Prudential Financial Inc. now owns 77,390 shares of the biopharmaceutical company’s stock valued at $981,000 after buying an additional 59,880 shares in the last quarter. Chicago Equity Partners LLC acquired a new stake in Horizon Pharma PLC in the third quarter valued at $1,726,000. Finally, Canada Pension Plan Investment Board raised its stake in Horizon Pharma PLC by 348.9% in the third quarter. Canada Pension Plan Investment Board now owns 101,900 shares of the biopharmaceutical company’s stock valued at $1,292,000 after buying an additional 79,200 shares in the last quarter. Institutional investors own 83.80% of the company’s stock.
A number of analysts have recently commented on HZNP shares. Jefferies Group LLC lifted their target price on Horizon Pharma PLC from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of Horizon Pharma PLC in a research report on Sunday, October 22nd. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 target price on shares of Horizon Pharma PLC in a research report on Monday, September 11th. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Sunday, October 15th. Finally, ValuEngine cut Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.42.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded down $0.03 during mid-day trading on Wednesday, reaching $13.04. The company had a trading volume of 260,698 shares, compared to its average volume of 3,517,239. The firm has a market cap of $2,200.00, a PE ratio of 9.72, a PEG ratio of 1.14 and a beta of 1.32. Horizon Pharma PLC has a 1 year low of $9.45 and a 1 year high of $21.98. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52.
Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. The firm had revenue of $271.60 million for the quarter, compared to analysts’ expectations of $259.74 million. Horizon Pharma PLC had a positive return on equity of 20.22% and a negative net margin of 45.28%. The firm’s revenue for the quarter was up 30.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 EPS. equities research analysts predict that Horizon Pharma PLC will post 0.72 earnings per share for the current year.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.